Nucleic Acid Metabolism in Patients with Severe Burn Injury and the Possibility of Its Correction

Purpose. To assess changes in nucleic acid (NA) metabolism in severe burn injury and to develop recommendations for correction of the alimentary status taking into account changes in the NA metabolism. Materials and methods. All patients (37 patients with II–III degree thermal burns and a burn area of more than 40%) were divided into 2 groups: Group I included survivors (23 patients), group II consisted of the deceased. The intensity of the NA metabolism was assessed based on the dynamics of the of uric acid (UA) and oligonucleotides serum concentrations. Results. In the acute period of burn injury, marked decrease in UA levels (less than 100 μmol/l), with gradual stabilization in survivors is typical. In addition, a 2–3-fold increase in the concentration of serum oligonucleotides compared to the normal limit is typical for survivors in the acute period, and these changes were significantly different from the group of deceased patients starting from day 5. Taking into account the data obtained, the level of serum UA can be recommended in clinical practice for the assessment of alimentary status in burn disease, as well as a criterion for f the prescription of glutamine administration in critically ill patients. In patients with burn disease a decrease in the UA level to less than 100 μmol/l was regarded as an absolute indication for the use of L-glutamine products. The use of glutamine in patients with significant decrease in UA levels was accompanied by a significant increase in the intensity of NA metabolism, which was demonstrated by both an increase in uric acid levels (by 85% by day 10 after the start of glutamine administration, P<0.01) and restoration of repair processes. Conclusion. Therefore, there was a marked alteration of NA metabolism in both groups of patients with severe burn injury. At the same time, surviving patients are characterized by rapid recovery of NA metabolism. Glutamine was employed as a pharmacological agent that effectively abrogates the depression of NA metabolism.

1. Peshkova I.V., Bogachev S.S., Drobyazgin E.A., Chikinev Y.V., Mitrofanov I.M., Piontkovskaya K.A., Vereschagin E.I. Effect of glutamine on the nucleic acids exchange during the perioperative period in reconstructive oesophagus surgery. J. Nutr. Health Food Eng. 2015; 2 (4): 108-112. DOI: 10.15406/jnhfe.2015.02.00058

2. Valeyeva V.A., Vereshchagin E.I., Berkasova I.V., Streltsova E.I. Indicators of nucleinic acids exchange at patients with abdominal sepsis. Meditsina i Obrazovanie v Sibiri. 2012; 6: 60. [In Russ.]

3. Naborshchikov D.A., Vereshchagin E.I., Smagin A.A., Streltsova E.I. Continuous substitutive renal therapy in treatment of serious destructive pancreatitis. Meditsina i Obrazovanie v Sibiri. 2012; 6: 42. [In Russ.]

4. Vlassov V.V., Laktionov P.P., Rykova E.Y. Extracellular nucleic acids. Bioessays. 2007; 29 (7): 654-667. DOI: 10.1002/bies.20604. PMID: 17563084

5. Alekseyev A.A., Krutikov M.G., Shlyk I.V., Levin G.Ya., Ushakova T.A., Tyurnikov Yu.I., Bogdanov S.B., Bobrovnikov A.E. Diagnosis and treatment of burn shock. Clinical recommendations. Moscow; 2014: 17. [In Russ.]

6. Singer P., Berger M.M., Van den Berghe G., Biolo G., Calder P., Forbes A., Griffiths R., Kreyman G., Leverve X., Pichard C.; ESPEN. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin. Nutr. 2009; 28 (4): 387–400. DOI: 10.1016/j.clnu.2009.04.024. PMID: 19505748

7. Newsholme E.A., Crabtree B., Ardawi M.S. Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. Q. J. Exp. Physiol. 1985; 70 (4): 473–489. DOI: 10.1113/expphysiol. 1985.sp002935. PMID: 3909197

8. Bollhalder L., Pfeil A.M., Tomonaga Y., Schwenkglenks M. A systematic literature review and meta-analysis of randomized clinical trials of parenteral glutamine supplementation. Clin. Nutr. 2013; 32 (2): 213–223. DOI: 10.1016/j.clnu.2012.11.003. PMID: 23196117

9. Wischmeyer P.E., Dhaliwal R., McCall M., Ziegler T.R., Heyland D.K. Parenteral glutamine supplementation in critical illness: a systematic review. Crit. Care. 2014; 18 (2): R76. DOI: 10.1186/cc13836. PMID: 24745648 10.Smedberg M., Wernerman J. Is the glutamine story over? Crit. Care. 2016; 20 (1): 361. DOI: 10.1186/s13054-016-1531-y. PMID: 27829456

10. Gamrin L., Essén P., Forsberg A.M., Hultman E., Wernerman J. A descriptive study of skeletal muscle metabolism in critically ill patients: free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes. Crit. Care Med. 1996; 24 (4): 575–583. DOI: 10.1097/00003246-199604000-00005. PMID: 8612406

11. Tjader I., Rooyackers O., Forsberg A.M., Vesali R.F., Garlick P.J., Wernerman J. Effects on skeletal muscle of intravenous glutamine supplementation to ICU patients. Intensive Care Med. 2004; 30 (2): 266–275. DOI: 10.1007/s00134-003-2048-9. PMID: 14722645

12. Ahlman B., Ljungqvist O., Persson B., Bindslev L., Wernerman J. Intestinal amino acid content in critically ill patients. JPEN. J. Parenter. Enteral. Nutr. 1995; 19 (4): 272–278. DOI: 10.1177/0148607195019004272. PMID: 8523625

13. Hammarqvist F., Wernerman J., Ali R., von der Decken A., Vinnars E. Addition of glutamine to total parenteral nutrition after elective abdominal surgery spares free glutamine in muscle, counteracts the fall in muscle protein synthesis, and improves nitrogen balance. Ann. Surg. 1989; 209 (4): 455–461. DOI: 10.1097/00000658-198904000-00011. PMID: 2494960

14. van der Hulst R.R., van Kreel B.K., von Meyenfeldt M.F., Brummer R.J., Arends J.W., Deutz N.E., Soeters P.B. Glutamine and the preservation of gut integrity. Lancet. 1993; 341 (8857): 1363–1365. DOI: 10.1016/0140-6736(93)90939-E. PMID: 8098788